In this guest analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines emerging clinical evidence on cannabidiol (CBD) as a sleep aid, contextualizing it against widespread sleep disorders in the U.S. He reviews a large peer-reviewed study showing that low doses of CBD can improve sleep quality with a favorable safety profile, performing comparably to melatonin, and without added benefit from minor cannabinoids. The article emphasizes both the promise and the limits of current evidence, underscoring the importance of product quality, third-party testing, and realistic expectations when considering CBD for sleep.

In this NY Cannabis Insider guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines Google’s 2023 policy shift allowing limited advertising for compliant, hemp-derived CBD products. He explains how certification requirements, age and geography restrictions, and third-party testing create new, but highly regulated, digital marketing pathways, while also reinforcing quality and consumer protection standards. Mazza positions the change as a meaningful step toward legitimizing the CBD industry and reshaping public perception through responsible, transparent advertising.

In this Nutritional Outlook article, Scott Mazza, co-founder and COO of Vitality CBD, argues that the 2023 Farm Bill must resolve ongoing regulatory ambiguity around CBD in foods, beverages, and dietary supplements. He outlines how the lack of clear FDA pathways has led to widespread issues with product purity, potency, labeling accuracy, and consumer safety, citing data on contamination and mislabeling across the market. Mazza calls for defined federal standards and enforcement, particularly around supplements and emerging cannabinoids like delta-8 THC, to protect consumers while providing long-term regulatory certainty for responsible producers.

In this analysis, Scott Mazza of Vitality CBD reviews recent peer-reviewed studies suggesting CBD may reduce opioid reward, support pain management, and enhance the effectiveness of naloxone in overdose response. He emphasizes that while these findings point to meaningful medical potential, widespread mislabeling, contamination, and lack of regulatory oversight currently undermine safe clinical use. The article argues that FDA guidance, medical-grade production standards, and routine third-party testing are essential for CBD to play a credible role in addressing the opioid crisis.

In this guest column, Scott Mazza of Vitality CBD examines emerging peer-reviewed research suggesting that cannabidiol may help reduce opioid reward, alleviate pain, and enhance the effectiveness of naloxone in overdose response. Mazza argues that these findings position CBD as a potentially valuable adjunct in addressing the opioid crisis, but only if products meet medical-grade standards for purity, potency, and consistency. The article stresses that meaningful clinical application will depend on stricter regulation, independent testing, and the elimination of low-quality products that currently undermine safety and credibility.

In this policy-focused opinion piece, Scott Mazza of Vitality CBD examines how court-ordered injunctions and regulatory uncertainty have stalled New York’s adult-use cannabis retail rollout, leaving qualified applicants in limbo. Drawing on firsthand experience pursuing a retail license in an affected region, Mazza outlines the consequences of delayed guidance, uneven enforcement against gray-market operators, and mounting legal costs. The article argues that clearer timelines, transparency around standard licensing, and stronger action against illicit sales are essential to restoring fairness and stability in New York’s legal cannabis market.

In this guest column, Scott Mazza of Vitality CBD explains how terpenes (the aromatic compounds in cannabis) contribute to distinct physiological effects and play a critical role alongside cannabinoids in the entourage effect. Citing a large-scale study analyzing thousands of real-world consumption sessions, Mazza highlights evidence that specific terpene profiles are associated with different outcomes for pain, anxiety, and depression. The article argues that moving beyond strain names toward chemistry-based classification could improve transparency, product selection, and medical credibility across both cannabis and CBD markets.

In this evidence-focused commentary, Scott Mazza of Vitality CBD examines what current research does (and does not) support regarding CBD’s role in women’s health. He reviews early findings on menopause-related symptoms, anxiety, and inflammation while cautioning that the largely unregulated CBD market has enabled misleading claims and inconsistent product quality. The article emphasizes responsible use, third-party testing, and the need for continued clinical research as the sector matures toward more credible, science-led outcomes.

In this expert-led analysis, Scott Mazza of Vitality CBD explains why the “entourage effect”, the synergistic interaction of cannabinoids, terpenes, and flavonoids, is increasingly central to understanding CBD efficacy. Drawing on emerging clinical evidence, including anxiety studies comparing full-spectrum products to CBD isolates, Mazza outlines how full-spectrum formulations may achieve therapeutic effects at lower doses with fewer side effects. The article emphasizes the need for rigorous research to move the entourage effect from theory to practice and to inform higher scientific and manufacturing standards across the CBD industry.

In this guest column, Scott Mazza of Vitality CBD outlines how emerging clinical research, particularly phase 2 data on anxiety and studies on menopause, signals a shift from anecdotal claims toward scientific validation of CBD. Mazza argues that regulatory inaction around CBD, Delta-8, and dietary supplement status continues to hinder industry legitimacy, calling for clearer federal oversight and enforcement against low-quality products. He also points to changing social attitudes, especially in sports and mainstream sponsorships, as evidence that CBD is entering a more mature and credible phase heading into 2023.

In this guest analysis, Scott Mazza, co-founder of Vitality CBD, examines emerging clinical evidence supporting CBD’s role in anxiety treatment, citing a Phase 2 trial showing significant symptom reduction with low-dose, full-spectrum CBD oil. Mazza highlights improvements in mood, sleep, and cognitive function, underscores the potential advantages of full-spectrum formulations over isolates, and calls for continued clinical research to establish standardized dosing and therapeutic guidance.

In this expert analysis, Scott Mazza, co-founder of Vitality CBD, examines the emerging science behind CBD use in pets, with a focus on arthritis, inflammation, and anxiety. Drawing on early peer-reviewed studies and veterinary insights, Mazza outlines evidence-based dosing considerations and stresses the importance of organic, lab-tested, pet-specific formulations as consumer interest in animal CBD wellness accelerates in the UK and globally.